ADORA2A and cancer: Therefore, an ideal approach for completely abrogating the immunosuppressive effects of the hypoxia-adenosine-A2AR axis might be the co-administration of both anti-hypoxia-HIF-1α therapies and A2AR antagonists during cancer immunotherapy (90).